1. It's like a **Fresenius Medical Care** (for dialysis equipment) crossed with a **Pentair** (for high-tech water purification).

2. Imagine a company that's a bit like **Ecolab** for advanced water hygiene, but also develops medical devices for kidney patients.

• Water Filtration Products: High-performance ultrafiltration products and general water filters designed to remove contaminants, prevent infections, and improve water quality for medical, commercial, and other applications.
• Real-time Water Testing Systems: Systems that provide actionable data for the real-time detection of waterborne pathogens.
• Hemodiafiltration System: A medical device, specifically a 2nd generation hemodiafiltration system, for treating patients with end-stage renal disease.

Nephros (NEPH) sells its products primarily to other companies and institutions rather than directly to individuals. Based on the provided company description, its major customer categories include:

• Healthcare Facilities: This category encompasses dialysis centers, hospitals (for infection prevention and potentially for renal disease systems), and other general healthcare facilities.
• Commercial Enterprises: This includes businesses in the food service, hospitality, and convenience store sectors that utilize Nephros' water filters for taste, odor, and equipment protection.
• Other Institutional Markets: This broad category covers customers such as military facilities and outdoor recreation facilities.

Robert Banks, President & Chief Executive Officer

Robert Banks was appointed President and Chief Executive Officer of Nephros in May 2023. He is responsible for leading the organization, developing and executing its strategy, and managing resources effectively. Banks has over two decades of experience in the water industry. Before joining Nephros, he spent nearly 20 years at GE, holding various commercial and engineering roles within small and medium-sized business units. He has a proven track record of growing sales across multiple businesses.

Judy Krandel, Chief Financial Officer

Judy Krandel was appointed Chief Financial Officer of Nephros in November 2023. She is responsible for driving effective financial strategies, maintaining the company's fiscal health, and adding value for investors and stakeholders. Krandel brings more than 20 years of experience in asset management, investment, operations, reporting, and oversight, coupled with formal accounting expertise. Prior to Nephros, she served as CFO at Recruiter.com and Paltalk Inc., both publicly traded companies.

Michael Milman, VP, R&D & Manufacturing

Michael Milman is the VP, R&D & Manufacturing at Nephros. He is responsible for defining and executing the strategic direction, research, development, and commercialization of the company's medical and commercial products. Milman has 20 years of experience in the electronics and medical device industries, with a strong record of matching industry needs with technology opportunities, bringing new products through manufacturing to market, and leading technical teams.

Vashone Thomas, VP, Quality, Regulatory, & Human Resources

Vashone Thomas serves as the VP, Quality, Regulatory, & Human Resources at Nephros.

Devorah Serkin, Senior Director, Revenue Operations

Devorah Serkin is the Senior Director, Revenue Operations at Nephros. She is responsible for overseeing company operations that directly drive revenue and developing and strengthening internal operations to provide streamlined experiences for customers. Serkin holds a Bachelor of Art in History from Binghamton University, a Master of Business Administration from Tel Aviv University, and graduated with distinction from the Harvard Business Analytics Program.

1. Customer and Supplier Concentration: Nephros is highly dependent on a limited number of customers and a key supplier. In 2025, three customers alone accounted for 44% of the company's revenue. Furthermore, a renewed supply agreement with Medica, a critical supplier, extends through 2030 and includes increasing euro-denominated minimum purchase commitments. This concentration exposes Nephros to significant risks such as demand shortfalls, currency fluctuations, and shifts in tariff policies affecting EU imports.
2. Impact of Tariffs and Margin Uncertainty: Unpredictable U.S. tariff policies have already led to a contraction in Nephros's gross margin during the second half of 2025. The ongoing uncertainty surrounding these tariffs creates a significant risk to future profitability and financial performance.
3. Challenges in Expanding into Commercial and Non-Patient Care Markets: While Nephros aims to expand its reach, particularly into commercial and non-patient care segments, these markets lack the strong regulatory tailwinds present in its traditional patient care business. Management has identified market inertia as a barrier, requiring substantial investment in education and awareness to drive product adoption in these less-regulated environments. This presents a hurdle to achieving anticipated growth outside its core medical markets.

Nephros, Inc. (NEPH) operates in several addressable markets with substantial global and regional opportunities for its water filtration, pathogen detection, and renal products.

Water Filtration

• Dialysis Centers: The global market for dialysis water filters was estimated at US$643 million in 2024 and is projected to reach US$882 million by 2031, growing at a CAGR of 4.9% during the forecast period of 2025-2031. Nephros serves approximately 7,500 dialysis centers in the U.S. Hemodialysis machines, water treatment systems, and ancillary disposables represented 56.05% of the renal dialysis equipment market in 2025.
• Hospitals (Infection Prevention): The global hospital filtration market is projected to grow from USD 2.10 billion in 2024 to USD 3.19 billion by 2030, at a compound annual growth rate (CAGR) of 7.2%. More broadly, the global infection control market was estimated at USD 52.38 billion in 2024 and is projected to reach USD 74.21 billion by 2030, with a CAGR of 6.1%. Hospitals accounted for the largest revenue share in the infection control market in 2024 and are expected to continue to grow rapidly. The global Legionella testing market, a specific area of infection prevention, was valued at USD 305.84 million in 2024 and is projected to reach USD 678.86 million by 2034, registering a CAGR of 8.3%. North America holds the largest share in the Legionella testing market. Nephros serves approximately 6,200 hospitals in the U.S.
• Commercial Markets (Food Service, Hospitality, Healthcare Facilities): The global commercial water filtration market size was valued at approximately USD 6 billion in 2024 and is projected to reach USD 7 billion by 2030, growing at a CAGR of about 3%. Another estimate places the global commercial water filter market size at USD 21.25 billion in 2024, projected to grow to USD 84.92 billion by 2035, exhibiting a CAGR of 13.42%. Nephros identifies a specific market opportunity of $10 million in Puerto Rico for healthcare, foodservice, and hospitality sectors.

Pathogen Detection

• Real-time Water Testing Systems: The global pathogen testing market was valued at USD 4.81 billion in 2024 and is projected to reach USD 8.37 billion by 2032, exhibiting a CAGR of 8.4%. The global water testing market size is estimated at USD 4.83 billion in 2026, with projections to reach USD 6.26 billion by 2031, growing at a 5.32% CAGR. Specifically, the global microbiological testing of water market is expected to reach $2.3 billion by 2027, growing at a steady 7.4% annually from its 2024 value of $1.6 billion.

Renal Products

• Hemodiafiltration Systems for End-Stage Renal Disease (ESRD): The global Medical Hemodiafiltration Machine market is projected to reach an estimated $38.1 billion by 2025, expanding at a CAGR of 5.66% from 2025 to 2033. The broader global renal dialysis equipment market is expected to grow from USD 22.40 billion in 2025 to USD 30.33 billion by 2031, at a 5.18% CAGR. The overall End-Stage Renal Disease market was valued at USD 140.90 billion in 2025 and is expected to increase to USD 340.84 billion by 2032, at a CAGR of 13.5%. The global Home Dialysis Systems Market size was valued at USD 24.69 billion in 2024 and is poised to grow to USD 60.64 billion by 2033, growing at a CAGR of 10.5%. Hemodialysis accounted for over 86.41% of global revenue for home dialysis systems in 2021.

Here are 3-5 expected drivers of future revenue growth for Nephros (NEPH) over the next 2-3 years:

1. Expansion into New Markets: Nephros is actively expanding its reach beyond traditional patient care settings into broader commercial markets, including food service and hospitality. A notable example is the company's entry into the Puerto Rican market, which is estimated to represent a $10 million opportunity across healthcare, foodservice, and hospitality sectors. This strategic expansion is aimed at leveraging advanced technology to meet critical water safety needs.
2. Product Innovation and New Product Launches: The company's significant revenue growth is partly attributed to ongoing innovations in the medical device sector and the introduction of new products. Recent product launches are enabling Nephros to address new high-impact applications, such as for ice machines and drinking water, thereby broadening its market appeal and utility.
3. Growth in Active Customer Sites and Programmatic Reorders: A key driver of consistent revenue growth for Nephros is the increasing number of active customer sites and strong programmatic reorder activity. In 2025, active customer sites grew to approximately 1,681 from about 1,500 at the end of 2024, and programmatic sales constituted over 90% of the company's revenue. This indicates a growing and sticky customer base that contributes to predictable, recurring revenue streams.
4. Leveraging Stricter Water Safety Standards and Regulatory Landscape: Stricter water safety standards, such as new water management guidance like ASHRAE 514, are creating tailwinds for Nephros. These evolving regulatory requirements are enabling the company's expanded salesforce to position Nephros' solutions prominently within healthcare facilities, as its infection control water filters are well-suited to fulfill the latest directive recommendations.
5. Enhanced Service Offerings and Educational Initiatives: Nephros is focused on advancing its service offerings through expanded installation and replacement capabilities, which helps reduce barriers to adoption and increase opportunities for recurring revenue. Additionally, the launch of the Nephros Water Institute establishes the company as an authority in waterborne pathogen mitigation and facility water safety, fostering greater engagement with customers and industry stakeholders, and supporting long-term demand for its filtration and compliance-driven solutions.

Share Issuance

Inbound Investments

Capital Expenditures